Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A ( K i =1.5 nM) and 5-HT2A ( K i =2.5 nM), and has antagonist activity at 5-HT2B ( K i =0.19 nM), and 5-HT7 ( K i =2.7 nM) receptors Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo . In Vivo Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SD-ratsDosage: 10 mg/kg Administration: Oral gavage; twice daily; 28 days Result: Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH. Form:Solid IC50& Target:5-HT|1A|Receptor|1.5 nM (Ki)|5-HT|2A|Receptor|2.5 nM (Ki)|5-HT|2B|Receptor|0.19 nM (Ki)|5-HT|7|Receptor|2.7 nM (Ki)|D|2|Receptor|D|3|Receptor|D|4|Receptor